- Treatment of idiopathic membranous nephropathy with chlorambucil and cyclosporineí2000 | First Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. BO21004Publication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. CC-5013-CLL-008Publication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. PCYC-1130-CAPublication without faculty affiliation
- Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group2020 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Third Faculty of Medicine
- Chlorambucil conjugates of dinuclear p-cymene ruthenium trithiolato complexes: synthesis, characterization and cytotoxicity study in vitro and in vivo2016 | Faculty of Medicine in Hradec Králové
- First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial2022 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial2019 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial2023 | Faculty of Medicine in Hradec Králové
- Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab2019 | First Faculty of Medicine
- Chemotherapy, radiotherapy and surgery in chronic lymphocytic leukemia treatment2010 | Third Faculty of Medicine
- Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study2023 | Publication without faculty affiliation
- Frontline treatment with the combination obinutuzumab +/- chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group2020 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab2014 | Faculty of Medicine in Hradec Králové
- Monoclonal Antibodies in the Treatment of Chronic Lymphocytic Leukemia in 20152015 | First Faculty of Medicine
- Report of University Hospital Hradec Králové to the clinical trial protocol No: PCYC-1115-CAPublication without faculty affiliation
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma2017 | First Faculty of Medicine
- Therapy of elderly/comorbid patients with chronic lymphocytic leukemia2013 | Faculty of Medicine in Hradec Králové
- A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL2016 | Faculty of Medicine in Hradec Králové
- The terapeutic Options for ""Slow- go"" Patients with Chronic Lymphocytic Leukemia2015 | Faculty of Medicine in Hradec Králové
- Treatment of elderly and comorbid patients with chronic lymphocytic leukemia2017 | Faculty of Medicine in Hradec Králové
- Long-term outcome of patients with idiopathic membranous nephropathy2006 | First Faculty of Medicine
- Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities2022 | Publication without faculty affiliation
- Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study2021 | Faculty of Medicine in Hradec Králové
- Therapeutic Approach to Patients with Chronic Lymphocytic Leukemia and Significant Comorbid Conditions2016 | Faculty of Medicine in Hradec Králové
- Unusual periungual nodulocystic lesions leading to the diagnosis of extranodal marginal zone lymphoma2020 | Third Faculty of Medicine
- Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia2015 | Publication without faculty affiliation
- Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma2018 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial2016 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?2021 | Faculty of Medicine in Hradec Králové